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CMS Quality Initiatives Series
Part III: Smoking Cessation
By: Carolyn Smith, PharmD
Health-System Pharmacy Administration Resident
Health care is always a top priority in this country and often the
topic of discussion and debate.
In 2004, Medicare spent $300
billion on health care costs, making it the largest purchaser of
healthcare in the nation.1
In an effort to improve the quality of health care and decrease
costs, the Department of Health
and Human Services (DHHS)
and the Centers for Medicare
and Medicaid Services (CMS)
have joined to create a program
called the Quality Initiative. The
purpose of the initiative is to encourage health care providers to
enhance the quality of care by
providing financial incentive and
to empower consumers with
quality of care information to
make more informed decisions
about their health care. The details regarding the initiatives are
described in the March issue.
(www.musc.edu/pharmacyservices/PnT/Mar07.pdf )

This month the focus will be
smoking cessation. Even with
documented evidence that cigarette smoking is directly correlated with the diagnosis of lung
cancer, congestive heart failure

and other illnesses, it is estimated
that 3,000 teens start smoking
daily.1,2 In the United States, cigarette smoking is considered on the
most major preventable causes of
disease.3 Although the number of
adults in the US who have identified themselves as smokers has
decreased from 22.5% to 20.9%
over the past 4 years, 9.3% of people over the age of 65 still smoke
cigarettes.1,4 This population is at
risk for coronary diseases, diabetes, and other chronic illnesses
associated with an increased risk
of mortality and morbidity.1
Several public health efforts have
been implemented in an attempt to
impact smoking behavior in the
American population.3,5 Some of
these efforts include restricting the
sale of tobacco and tobaccorelated products to people over the
age of 18, establishing laws that
prohibit smoking within public
buildings (eg, workplaces, restaurants and bars), restricting advertisements for tobacco products,
and taxing of tobacco products to
increase the price.3,5 Even with
these efforts, estimated sales of
cigarettes is still increasing and is
currently in excess of 5 trillion
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cigarettes per year.3 Recent efforts to help people quit smoking
include the CMS decision to cover
healthcare services including prescription medications and counseling in the elderly population.1
Helping patients quit smoking
would not only decrease the expenditure of treating smokingrelated illnesses, but would promote wellness in Medicare patients.1 Smoking cessation shows
clear health benefits even in patients who have smoked for more
than 30 years, including decreasing the risk of new myocardial
infarction, improving lung function in COPD patients, and reducing the risk of lung cancer, tuberuculosis, pneumococcal infection, peptic ulcer disease, reproductive disorders, and osteoporosis.3
CMS Quality Indicators
CMS includes smoking cessation
in several Quality Initiatives, including, heart failure, acute myocardial infarction, and pneumonia.
For more information regarding
these specific Iniatives, please refer to the P&T Newsletters for
March, April/May, and August/
September 2007. The indicator
specific to smoking states that patients with a history of smoking
should receive smoking cessation
advice or counseling during their
hospital stay. A history of smoking is defined as someone who has
smoked cigarettes anytime during
the year prior to hospital arrival.
Hospitalization can be an ideal
opportunity for a patient to stop
smoking, and smoking cessation
may promote the patient’s medical
recovery. Patients who receive
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even brief smoking cessation
advice from their health care
providers are more likely to quit
than those who receive no counseling whatsoever.
To be compliant with the CMS
indicators, it is important to
document in the patient’s medical record that cessation counseling was provided. Table 1 provides the printed order forms
that have specified areas for
documentation.
Smoking Cessation Counseling
The exact mechanism for providing cessation counseling is
not defined by CMS. It is important to discuss the risks of
continued smoking, the benefits
of cessation, the methods or
treatment options available to
assist in cessation, and the challenges the patient may face.
Two primary methods for smoking cessation can be employed;
counseling and medication therapy. Individual or group counseling has been shown to be an
effective treatment option and
should be used with all patients
attempting to quit smoking.1
Two types of counseling can be
employed, intermediate or intensive.1 Intermediate counseling

sessions range from 3 to 10 minutes, and intensive sessions occur
over greater than 10 minutes.1
CMS will cover both intensive
and intermediate counseling with
a maximum of 4 counseling sessions per quit attempt, allowing
patients up to 2 quit attempts per
year.1
The behavioral approach that is
utilized in counseling sessions is
often referred to as the 5As.3 The
steps are as follows: 3
▪ Assess the patient’s smoking status
▪ Assess the patient’s willingness to quit
▪ Advise the smoker to quit
▪ Assist them with their cessation efforts
▪ Arrange for follow-up visits
Alternative therapies such as hypnosis and acupuncture exist as
well.3 In addition to counseling,
effective medication therapy can
double or triple patients’ chances
of smoking cessation.3 First line
medication therapy includes nicotine replacement, as well as the
use of bupropion sustained release
(Zyban®)
and
varenicline
® 6,7
Second line medi(Chantix ).
cation therapy includes medications such as nortriptyline, clonidine, and combination nicotine
therapy.6,7
It is important to note that success
often hinges on implementation

Table 1. Documentation for Cessation Counseling
1. Check boxes on History and Physical (H&P)
Inpatient H&P Form (checkbox on pages 6 & 7):
www.musc.edu/cce/ORDFRMS/pdf/longhp.pdf
Medication Reconciliation Form:
www.musc.edu/cce/ORDFRMS/pdf/medreconciliation.pdf
2. Use selected clinician order forms for guidance:
Adult Universal Admission Orders:
www.musc.edu/cce/ORDFRMS/pdf/universaladmit.pdf
Discharge Orders (checkbox pg 2):
www.musc.edu/cce/ORDFRMS/pdf/dischgeneral.pdf
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and follow through of a full plan
including an evaluation process
for determining success or failure
of therapy, alternative options,
and a follow-up approach.
Medication Therapy
It is often difficult for patients to
quit smoking “cold turkey” due to
the effects associated with nicotine withdrawal such as insomnia,
irritability, anxiety, restlessness,
difficulty concentrating, increased
appetite, and weight gain.3
Products that provide nicotine
supplementation reduce the severity of withdrawal symptoms, severity of cravings, and reinforcing
effects of tobacco-delivered nicotine.6 The product chosen is patient specific. Table 2 contains

more information on prescribing
of nicotine replacement products.
The polacrilex gum and lozenge
are available over the counter
and have been shown to reduce
the intensity of discomfort associated with withdrawal symptoms.3
Transdermal nicotine
patches are available over the
counter as well.3 As with the
gum and lozenge, the patch
helps reduce, but not eliminate
Prewithdrawal symptoms.3
scription nicotine replacement
products include the nasal spray
and inhaler. The nasal spray delivers nicotine similarly to smoking a cigarette.3
The spray
raises serum nicotine concentrations more rapidly than the patch

or gum/lozenge.3 This is important to keep cravings and withdrawal symptoms under control.9
The nicotine inhaler delivers nicotine via buccal absorption, and
produces slow absorption that
reaches concentrations only about
1/3 of that normally experienced
from cigarettes.3
Bupropion
sustained
release
®
(Zyban ) was the first nonnicotine medication approved by
the FDA for smoking cessation.8
The abstinence rate with bupropion has been shown to be approximately 30%.10 Specific prescribing information is located in
Table 2. Bupropion can cause insomnia so it is recommended that
the second dose be taken in the
late afternoon, at least 8 hours af-

Table 2. Nicotine Replacement Products
Medication
Nicotine gum
(Nicorette®)

Dose
2 or 4 mg
[2 mg: < 25 cigarettes a day]
[4 mg: ≥ 25 cigarettes a day]

Administration
Week 1 to 6: 1 piece every 1 to 2 hrs
Week 7 to 9: 1 piece every 2 to 4hrs
Week 10 to 12: 1 piece every 4 to 8 hrs

Counseling Points

▪ Must use at least 9 pieces of
▪

**Do not use > 24 pieces/day**
Nicotine lozenge
(Commit®)
nonformulary

Nicotine patches
(Nicoderm®)

2 or 4 mg
Time to first cigarette in AM:
≤ 30 min: 4 mg
> 30 min: 2 mg
21 mg/day
14 mg/day
7 mg/day
Taper doses according to
administration directions

Nicotine inhaler
(Nicotrol®)
nonformulary
Nicotine nasal
spray
(Nicotrol®)
nonformulary

10 mg cartridges
(4 mg delivered)
10 mg/mL
0.5 mg nicotine/spray
1 dose = 1 mg in each nostril

Week 1 to 6: 1 lozenge every 1 to 2 hrs
Week 7 to 9: 1 lozenge every 2 to 4 hrs
Week 10 to 12: 1 lozenge every 4 to 8 hrs

▪
▪
▪

Smoking history > 10 cigarettes/day:
▪ Use 21 mg patch/day for 4 to 6 wks;
▪ Then use 14 mg patch/day for 2 wks;
▪ Then use 7 mg patch/day for 2 wks
Smoking history ≤ 10 cigarettes/day:
▪ Use 14 mg patch/day for 6 wks;
▪ Then use 7 mg patch/day for 2 wks
Weeks 1-12: 6 to 16 cartridges/day
Weeks 13-24: titrate to lower dose, then
off
Weeks 1-8: 1 spray in each nostril
1 to 2 times/hr; at least 8 times/day
Weeks 9-14: gradually taper over
4 to 6 wks

gum/day for 12 weeks
Avoid drinking and eating
with in 15 minutes of
using gum
Gum is not chewed
Must use 12 to 24 lozenges /day for at least
6 weeks
Avoid drinking and eating
with in 15 minutes of lozenge administration

▪ Do not smoke cigarettes,
chew or snuff tobacco

▪ Dispose of patch properly
by folding in half

▪ Remove at bedtime if
wakefulness occurs
▪ Rotate application sites
1 time per week
Maximum dose:
16 cartridges/day
Maximum dose
5 times/hr
40 times/24 hr
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Table 3. Non-nicotine Smoking Cessation Products
Medication
Bupropion SR
(Zyban®)

**Bupropion
extended release (XL) is
indicated for
depression
only**
Varenicline
(Chantix®)
nonformulary

Mechanism of
Action
Blocks neural reuptake
of dopamine and/or
norepinephrine

Administration
First 3 days:
▪ 150 mg each morning
7 to 12 weeks:
▪ 150 mg 2 times a day
**Start 1 to 2 weeks
before the quit date**

▪ Blocks nicotine
binding to nicotinic
receptors
▪ Partially stimulates
the nicotinic receptor
to reduce cravings
and withdrawal
symptoms

Duration:
▪ 7 to 12 weeks
▪ Up to 6 months for
maintenance
Days 1-3
▪ 0.5 mg once daily
Days 4-7:
▪ 0.5 mg twice daily
Day 8-end of therapy:
▪ 1 mg twice daily

▪ Start 1 week before the

Adverse Effects

▪
▪
▪
▪
▪
▪
▪
▪
▪
▪
▪
▪
▪
▪
▪
▪
▪

Insomnia
Dry Mouth
Anaphylaxis
Cardiac dysrhythmia
Depression, exacerbation
Mania
Psychotic disorder
Seizure
Stevens-Johnson
syndrome
Suicidal thoughts
Nausea
Headaches
Abnormal dreams
Constipation
Flatulence
Vomiting
Change in taste perception

quit date

▪ Dose must be adjusted
for renal impairment

ter the first dose. It is contraindicated in patients with a seizure
history or a history of an eating
disorder. Bupropion can be used
in conjunction with nicotine replacement products to help reduce
the incidence of withdrawal symptoms.
The newest prescription medication is varenicline (Chantix®).3,6
This medication is a partial agonist of the nicotinic acetylcholine
receptor.3,6 Varenicline was shown
to be effective in reducing the
urge to smoke and patients were
more likely to maintain abstinence
throughout the follow-up period
(up to 44%) compared with placebo.10 If cessation is successful
in the first 12 weeks, then an additional 12 weeks may be com-

pleted.6 When compared with
bupropion sustained release,
varenicline proved to be equally
effective in achieving smoking
cessation.6 Varenicline is generally well tolerated with nausea
and vomiting being the most
common adverse effects. Prescribing information is located in
Table 3.
Patient Counseling Resources
In addition to speaking to patients about the smoking cessation, it is important to provide
them with the tools or resources.
Numerous useful smoking cessation resources are available on
the Internet for health care professionals and patients (Table 4).
Success depends on the patients’
willingness to quit. The effec-

Counseling Points

▪ Patient must have
quit date before
starting therapy
▪ Take second daily
dose early in the
afternoon to avoid
insomnia
▪ Maximum dose:
300 mg/day

▪ Patient must have
quit date before
starting therapy
▪ Take as directed
following pack
instructions
▪ Take after meal with
full glass of water to
decrease nausea
▪ Continue lower dose
if patient unable to
tolerate nausea
and vomiting

tiveness of counseling increases
with the intensity of treatment (ie,
session length, number of sessions, total minutes of contact).
Additionally, medication therapy
can double or triple the patients’
chances of abstinence. Approximately 50 to 60% of initially successful quitters relapse within a
year. Therefore, intensive smoking cessation should use a combination of behavioral counseling
and pharmacotherapy. It is
import
that
health care providers speak to
each
patient,
monitor his/her
progress regularly, and provide
encouragement along the way.
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Table 4. Smoking Cessation Resources
American Lung Association Smoking Cessation Support: www.lungusa.org/site/pp.asp?c=dvLUK9O0E&b=22931
Centers for Disease Control and Prevention: www.cdc.gov/tobacco/quit_smoking/how_to_quit/index.htm
National Cancer Institute: www.cancer.gov/cancertopics/factsheet/Tobacco/cessation
You Can Quit (MUSC Patient Handouts): www.musc.edu/medcenter/pted/HealthAndWellness/source/tobaccoCessation/index.htm
Family Medicine Clerkship: Smoking and Tobacco Addiction: http://fammed.musc.edu/fmc/data/Smoking.htm
Medlineplus: Smoking Cessation Patient Information: www.nlm.nih.gov/medlineplus/smokingcessation.html
Smoking Cessation: www.smoking-cessation.org/

▪ the use of aprotinin was asso-

Did You Know...
Early Communication about an
Ongoing Safety Review:
Aprotinin (Trasylol®)
FDA was notified of the recommendation by the Data Safety
Monitoring Board’s (DSMB) to
stop patient enrollment in the
aprotinin treatment group arm of
the: Blood conservation using
antifibrinolytics: A randomized
trial in a cardiac surgery population (BART) study. The preliminary findings suggest that, compared with the antifibrinolytic
drugs, aminocaproic acid and
tranexamic acid, aprotinin increases the risk of death.
Information from the interim
analyses performed by the DSMB
is limited, but FDA has been informed about the following:
▪ 30-day mortality in the aprotinin
group nearly had reached conventional statistical significance
at the interim analysis, when
compared with either aminocaproic acid or tranexamic acid;
▪ a trend toward increased mortality in the aprotinin group had
been observed;

ciated with less serious bleeding than either of the comparator drugs; however, more
deaths due to hemorrhage had
been observed among patients
receiving aprotinin;
▪ DSMB concluded that continued enrollment of patients into
the aprotinin group was
unlikely
to
significantly
change the study findings.
Additional data collection and
analyses must be performed to
more thoroughly assess the findings from the BART study.
However, these preliminary data
support the findings from observational studies that also suggested increased risks for mortality when aprotinin was compared to other antifibrinolytic
drugs.
FDA anticipates re-evaluation of
the overall risks and benefits of
aprotinin. Until this process has
been completed, healthcare providers who are considering use
of aprotinin should be aware of
the risks and benefits described
in the labeling and the accumulating data suggesting aportinin
administration may increase the
risk for death compared with
other antifibrinolytic drugs.

Pregnancy Category Change for
Mycophenolate Mofetil
(CellCept®)
Roche and FDA notified healthcare providers that use of mycophenolate mofetil is associated
with increased risk of first trimester pregnancy loss and increased
risk of congenital malformations,
especially external ear and facial
abnormalities including cleft lip
and palate, and anomalies of the
distal limbs, heart, esophagus, and
kidney. Based on postmarketing
data from the United States National Transplantation Pregnancy
Registry and additional postmarketing data collected in women
exposed to systemic mycophenolate mofetil during pregnancy,
the pregnancy category has been
changed from Category C to Category D (positive evidence of fetal
risk).
Within 1 week of beginning therapy, women of childbearing potential should have a negative
pregnancy test. In addition, these
women must receive contraceptive
counseling and use effective contraception. Healthcare professionals and patients should be aware
that mycophenlate mofetil reduces
blood levels of the hormones in
the oral contraceptives.
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FORMULARY UPDATE FOR SEPTEMBER 2007
The Pharmacy and Therapeutics
Committee recently approved the
actions listed below. The formulary effective date was October
15, 2007, unless otherwise noted.
Additions:
Fondaparinux (Arixtra®) is an antithrombotic agent approved for
deep vein thrombosis (DVT) prophylaxis in patients at risk for developing a pulmonary embolism
(PE). It is also approved for use
in combination with warfarin for
the treatment of acute DVT or PE.
Additionally, there are limited
data to support its use in patients
with a history of heparin-induced
thrombocytopenia (HIT) or for the
treatment of HIT.
2.5-, 5-, 7.5-, 10-mg syringes
Cocaine ophthalmic solution is
used for the diagnosis of Horner
syndrome (damage to the sympathetic nerves in the eye). This will
be available through the Compounding Center. It is important
to inform patients a urine drug
screen may show positive for cocaine for up to 48 hours after use.
3.7% extemporaneous ophthalmic solution
Recent FDA Generic Approvals
The following recently received
FDA approval as generic products:

▪ Carvedilol 3.125, 6.25, 12.5, and
25-mg tablets: for the treatment
of high blood pressure, mild to
severe chronic heart failure and
left ventricular dysfunction following myocardial infarction.
This medication is generic
equivalent of Coreg®.

Cefotetan (various) was deleted
from the formulary in 2006 due
to its unavailability from manufacturers.
It is again being
manufactured and is now currently available. Therefore, it
has been re-added to the formulary. Cefoxitin (Mefoxin®) will
also still remain on formulary.
1 and 2 grams
Line Extensions:
▪ Mitomycin ophthalmic drops
[0.2 mg/mL extemporaneous
ophthalmic solution]
▪ Clotrimazole 3-day vaginal
cream (2%) [21-g tube]
▪ Albuterol HFA Inhalers
(ProAir®) [8.5-g container]
Deletions:
▪ Repository corticotrophin injection (H.P. Acthar® Gel)
[This will not be available
through the nonformulary
process]
▪ Sodium diatrizoate
(Gastroview®)
Effective September 25, 2007

▪ Dalteparin (Fragmin®)
▪ Lidocaine (LMX-4®) cream
[30-g tube]

▪ Clotrimazole 7-day vaginal
cream (1%) [45-g tube]
Deletions (continued):
▪ Esmolol (Brevibloc®)
[250-mg/mL ampules]
▪ Digoxin
[0.05- and 0.1-mg capsules]
New/Updated Policies:
▪ Formulary Systems (C-82 )
▪ IV Push Administration - new
medical center policy
Other Action Items:
▪ The MUSC Continuous Infusion
Guidelines for Pediatric Patients (Pediatric Intensive Care
Unit) were updated to include
fenoldapam, insulin, and dexmedetomidine
▪ Children’s Hospital Pediatric
Inpatient Insulin Pump Orders:
standing preprinted order forms
for continuing insulin pumps in
diabetic pediatric inpatients being admitted to the hospital
▪ Children’s Hospital Pediatric
Hypoglycemia Standing Orders:
standing preprinted order forms
for a hypoglycemia protocol for
pediatric inpatients

▪ Hydrocodone and chlor-

▪ Oxcarbazepine 150-, 300-, and

pheniramine polistirex suspension: for relief of cough and
upper respiratory symptoms.
This medication is the generic
equivalent for Tussionex®
Pennkinetic Suspension.

600-mg tablets: for the treatment
of partial seizures in adults and
children 4 years of age and older.
The medication is the generic
equivalent of Trileptal®.

▪ Fosphenytoin sodium injection
(75-mg/mL): for treatment of
convulsions and seizures. This
medication is the generic
equivalent to Cerebyx®.

▪ Risedronate 5, 30, and 35 mg tablets: indicated for the treatment
and prevention of osteoporosis,
and the treatment of Paget disease. This medication is generically equivalent to Actonel®.

